Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...

Eli Lilly released a new form of its weight loss drug Zepbound for roughly half ... according to an update on the company's ...

Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...

The drugs are ... Ricks said. Lilly on Monday approved a program to buy back as much as $15 billion of its own shares amid rapid growth fueled by Zepbound and Mounjaro. The company also raised ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for ... [+] health insurers, employers and government health programs who cover it in 2025.

Eli Lilly shares ... billion for diabetes drug Mounjaro and $1.9 billion for Zepbound. That is much higher than a year earlier but short of analysts’ projections of $4.4 billion for Mounjaro and $2.1 ...

Eli Lilly expects 2024 revenue of $45.0 billion, reflecting a 32% increase, with strong contributions from Mounjaro and ...

Founded over 145 years ago in Indianapolis, pharmaceutical company Eli Lilly established its first ... some links to products and services on this website. Offers may be subject to change without ...

Eli Lilly has backed away from plans to file Alzheimer's drug donanemab in the first quarter of this year, saying the proposal to limit reimbursement of Biogen's first-to-market Aduhelm has made ...

Zepbound (tirzepatide), manufactured by Fortune 500 firm Eli Lilly & Co., bested competitor Wegovy (semaglutide), a product of Global 500 company Novo Nordisk, in a 2023–24 randomized clinical ...

Indianapolis-based Eli Lilly and Company chose Kenosha County for its latest — and one of its largest — investments. The pharmaceutical giant announced Thursday that it was planning a $3 ...